Bone Healing Treatment and Inflammation Levels in Smokers vs. Non-Smokers

Clinical Evaluation OF efficacy OF BOVINE DERIVED Xenograft In Treatment of Infrabony Defect along with Level OF CHEMOKINE EOTAXIN-1 IN SMOKER VS NON-SMOKER A CLINCO BIOCHEMICAL STUDY. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/083629

Enrollment

Registered

2025-03-28

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K038- Other specified diseases of hard tissues of teeth

Interventions

Intervention1: BIOSS Xenograft In Smoker AND Non Smoker Group.: BIOSS Xenograft In Smoker AND Non Smoker Group Control Intervention1: NOT APPLICABLE: NOT APPLICABLE

Eligibility

Inclusion criteria

Inclusion criteria: 1) Subjects clinically diagnosed with intrabony defects of more than 3mm depth. 2) Radiographic evidence of defect 3) Moderate smoker (10-19 cigarettes/day) 4) Patient willing to comply to treatment protocol

Exclusion criteria

Exclusion criteria: 1) Pregnancy and Lactation 2) Patients who have taken antibiotics in the previous 3 months 3) Failure to provide consent 4) Patients not maintaining oral hygiene

Design outcomes

Primary

Measure	Time frame
Pocket Probing Depth, Relative Attachment Level, Linear bone growth, Alveolar Crest Height, Defect Depth, Chemokine Eotaxin-1 level and Absolute eosinophilic count.Timepoint: Baseline, 3 months and 6 months.	—

Secondary

Measure	Time frame
Gingival Index and Plaque IndexTimepoint: Baseline, 3months and 6 months.	—

Countries

India

Contacts

Public ContactGaurav Das

ITS DENTAL COLLEGE MURADNAGAR

gauravdas429@gmail.com08826214798

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026